Solrikitug clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses solrikitug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Uniquity One (UNI) (2) · Merck Sharp & Dohme LLC (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses solrikitug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate Solriktug in Adult Participants With AsthmaCompletedPhase 2Uniquity One (UNI)NCT06496607Written as NSI-8226
- A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese ParticipantsCompletedPhase 1Uniquity One (UNI)NCT06868082Written as Solrikitug
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT01096160Written as MK-8226 BID, 1 mg
- A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01732510Written as MK-8226
Codes
What other systems call solrikitug · ClinicalTrials.gg INT018400
- UNII (FDA) WYT4WRY5YFSOLRIKITUGOne source FDA
- NCI Thesaurus C203159SolrikitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WYT4WRY5YF | SOLRIKITUG | One source FDA |
| NCI Thesaurus | C203159 | Solrikitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.